Financhill
Sell
33

AMGN Quote, Financials, Valuation and Earnings

Last price:
$292.54
Seasonality move :
5.47%
Day range:
$292.84 - $297.14
52-week range:
$253.30 - $346.85
Dividend yield:
3.12%
P/E ratio:
27.10x
P/S ratio:
4.71x
P/B ratio:
25.73x
Volume:
1.2M
Avg. volume:
2.7M
1-year change:
-10.22%
Market cap:
$159.7B
Revenue:
$33.4B
EPS (TTM):
$10.96

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AMGN
Amgen
$8.9B $5.24 5.03% 3.13% $313.56
GILD
Gilead Sciences
$7B $1.95 -0.13% 51.38% $116.85
JNJ
Johnson & Johnson
$22.9B $2.68 3.11% 143.36% $169.14
LLY
Eli Lilly and
$14.6B $5.54 34.58% 472% $952.27
MRNA
Moderna
$116.2M -$2.98 -49.84% -11.55% $47.59
REGN
Regeneron Pharmaceuticals
$3.3B $8.55 -7.35% -30.58% $728.55
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AMGN
Amgen
$297.03 $313.56 $159.7B 27.10x $2.38 3.12% 4.71x
GILD
Gilead Sciences
$112.09 $116.85 $139.4B 23.60x $0.79 2.78% 4.92x
JNJ
Johnson & Johnson
$156.82 $169.14 $377.3B 17.44x $1.30 3.2% 4.26x
LLY
Eli Lilly and
$799.34 $952.27 $717.6B 65.04x $1.50 0.7% 14.73x
MRNA
Moderna
$32.87 $47.59 $12.7B -- $0.00 0% 4.07x
REGN
Regeneron Pharmaceuticals
$570.59 $728.55 $61.6B 14.53x $0.88 0.31% 4.62x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AMGN
Amgen
90.24% -0.268 34.26% 0.74x
GILD
Gilead Sciences
56.56% 0.135 17.9% 1.00x
JNJ
Johnson & Johnson
40.08% 0.056 13.1% 0.96x
LLY
Eli Lilly and
70.96% -0.134 5.19% 0.57x
MRNA
Moderna
-- -0.100 -- 3.92x
REGN
Regeneron Pharmaceuticals
6.33% 0.047 2.89% 3.90x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
GILD
Gilead Sciences
$5.1B $2.5B 13.82% 32.29% 28.63% $1.7B
JNJ
Johnson & Johnson
$14.5B $6.3B 19.44% 30.18% 63.19% $3.4B
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
MRNA
Moderna
$17M -$1.1B -29.23% -29.23% -900% -$1.2B
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M

Amgen vs. Competitors

  • Which has Higher Returns AMGN or GILD?

    Gilead Sciences has a net margin of 21.23% compared to Amgen's net margin of 19.72%. Amgen's return on equity of 97.08% beat Gilead Sciences's return on equity of 32.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    63.58% $3.20 $63.6B
    GILD
    Gilead Sciences
    76.9% $1.04 $44B
  • What do Analysts Say About AMGN or GILD?

    Amgen has a consensus price target of $313.56, signalling upside risk potential of 5.56%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 4.24%. Given that Amgen has higher upside potential than Gilead Sciences, analysts believe Amgen is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    12 15 2
    GILD
    Gilead Sciences
    16 11 0
  • Is AMGN or GILD More Risky?

    Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

  • Which is a Better Dividend Stock AMGN or GILD?

    Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.12%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. Amgen pays 118.14% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios AMGN or GILD?

    Amgen quarterly revenues are $8.1B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Amgen's net income of $1.7B is higher than Gilead Sciences's net income of $1.3B. Notably, Amgen's price-to-earnings ratio is 27.10x while Gilead Sciences's PE ratio is 23.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.71x versus 4.92x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.71x 27.10x $8.1B $1.7B
    GILD
    Gilead Sciences
    4.92x 23.60x $6.7B $1.3B
  • Which has Higher Returns AMGN or JNJ?

    Johnson & Johnson has a net margin of 21.23% compared to Amgen's net margin of 50.24%. Amgen's return on equity of 97.08% beat Johnson & Johnson's return on equity of 30.18%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    63.58% $3.20 $63.6B
    JNJ
    Johnson & Johnson
    66.4% $4.54 $130.4B
  • What do Analysts Say About AMGN or JNJ?

    Amgen has a consensus price target of $313.56, signalling upside risk potential of 5.56%. On the other hand Johnson & Johnson has an analysts' consensus of $169.14 which suggests that it could grow by 7.86%. Given that Johnson & Johnson has higher upside potential than Amgen, analysts believe Johnson & Johnson is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    12 15 2
    JNJ
    Johnson & Johnson
    8 13 0
  • Is AMGN or JNJ More Risky?

    Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

  • Which is a Better Dividend Stock AMGN or JNJ?

    Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.12%. Johnson & Johnson offers a yield of 3.2% to investors and pays a quarterly dividend of $1.30 per share. Amgen pays 118.14% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

  • Which has Better Financial Ratios AMGN or JNJ?

    Amgen quarterly revenues are $8.1B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Amgen's net income of $1.7B is lower than Johnson & Johnson's net income of $11B. Notably, Amgen's price-to-earnings ratio is 27.10x while Johnson & Johnson's PE ratio is 17.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.71x versus 4.26x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.71x 27.10x $8.1B $1.7B
    JNJ
    Johnson & Johnson
    4.26x 17.44x $21.9B $11B
  • Which has Higher Returns AMGN or LLY?

    Eli Lilly and has a net margin of 21.23% compared to Amgen's net margin of 21.68%. Amgen's return on equity of 97.08% beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    63.58% $3.20 $63.6B
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About AMGN or LLY?

    Amgen has a consensus price target of $313.56, signalling upside risk potential of 5.56%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 19.13%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    12 15 2
    LLY
    Eli Lilly and
    18 4 1
  • Is AMGN or LLY More Risky?

    Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

  • Which is a Better Dividend Stock AMGN or LLY?

    Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.12%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.50 per share. Amgen pays 118.14% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

  • Which has Better Financial Ratios AMGN or LLY?

    Amgen quarterly revenues are $8.1B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Amgen's net income of $1.7B is lower than Eli Lilly and's net income of $2.8B. Notably, Amgen's price-to-earnings ratio is 27.10x while Eli Lilly and's PE ratio is 65.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.71x versus 14.73x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.71x 27.10x $8.1B $1.7B
    LLY
    Eli Lilly and
    14.73x 65.04x $12.7B $2.8B
  • Which has Higher Returns AMGN or MRNA?

    Moderna has a net margin of 21.23% compared to Amgen's net margin of -907.48%. Amgen's return on equity of 97.08% beat Moderna's return on equity of -29.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    63.58% $3.20 $63.6B
    MRNA
    Moderna
    15.89% -$2.52 $10.1B
  • What do Analysts Say About AMGN or MRNA?

    Amgen has a consensus price target of $313.56, signalling upside risk potential of 5.56%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 44.79%. Given that Moderna has higher upside potential than Amgen, analysts believe Moderna is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    12 15 2
    MRNA
    Moderna
    4 17 1
  • Is AMGN or MRNA More Risky?

    Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

  • Which is a Better Dividend Stock AMGN or MRNA?

    Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.12%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMGN or MRNA?

    Amgen quarterly revenues are $8.1B, which are larger than Moderna quarterly revenues of $107M. Amgen's net income of $1.7B is higher than Moderna's net income of -$971M. Notably, Amgen's price-to-earnings ratio is 27.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.71x versus 4.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.71x 27.10x $8.1B $1.7B
    MRNA
    Moderna
    4.07x -- $107M -$971M
  • Which has Higher Returns AMGN or REGN?

    Regeneron Pharmaceuticals has a net margin of 21.23% compared to Amgen's net margin of 26.7%. Amgen's return on equity of 97.08% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    63.58% $3.20 $63.6B
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About AMGN or REGN?

    Amgen has a consensus price target of $313.56, signalling upside risk potential of 5.56%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 27.68%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    12 15 2
    REGN
    Regeneron Pharmaceuticals
    14 7 0
  • Is AMGN or REGN More Risky?

    Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

  • Which is a Better Dividend Stock AMGN or REGN?

    Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.12%. Regeneron Pharmaceuticals offers a yield of 0.31% to investors and pays a quarterly dividend of $0.88 per share. Amgen pays 118.14% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMGN or REGN?

    Amgen quarterly revenues are $8.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Amgen's net income of $1.7B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Amgen's price-to-earnings ratio is 27.10x while Regeneron Pharmaceuticals's PE ratio is 14.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.71x versus 4.62x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.71x 27.10x $8.1B $1.7B
    REGN
    Regeneron Pharmaceuticals
    4.62x 14.53x $3B $808.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock